Yanfen Li1, Yu Jing1, Hua Wan2, Daihong Liu1. 1. Department of Hematology, Chinese PLA General Hospital. 2. Beijing USCI Medical Laboratory, Beijing, P.R. China.
Abstract
INTRODUCTION: Myeloid neoplasms with platelet-derived growth factor receptor β (PDGFRB) rearrangement usually present with eosinophilia in the peripheral blood and bone marrow. Here we report a case of systemic mastocytosis related myeloid neoplasms with basophilia and PRKG2-PDGFRB fusion gene. PATIENTS CONCERNS: A 53-year-old male patient felt fatigue with thrombocythemia and normal hemoglobin over 2 years. Considering the possibility of primary thrombocytosis, the patient was treated with hydroxyurea and interferon. Then the therapy was stopped due to adverse events and worsen condition. DIAGNOSIS: Acute myelogenous leukemia (AML) diagnosis was confirmed by bone marrow morphology and flow cytometry. PDGFRB rearrangement was detected by fluorescence in situ hybridization (FISH) test, with chromosome karyotype 46,XY,t(4:5)(q21:q33). PRKG2-PDGFRB fusion was observed by next generation sequencing (NGS) and verified by RT-PCR followed by Sanger sequencing. The results of bone marrow aspiration, bone marrow biopsy, and immunophenotyping showed systemic mastocytosis-related myeloid tumor with basophilia. INTERVENTIONS: Imatinib 400 mg/d was given on the day of admission. Azacitidine 75 mg/m2 was given for induction therapy for 10 days, and followed by one course of DHAG consolidating therapy. Imatinib was taken orally continuously. OUTCOMES: On the 8th day of treatment, the patient's diet and fatigue improved. The hematological and bone marrow morphological remission was achieved on the 25th day. Cytogenetic complete remission was achieved 3 months later and continued to present (December 20, 2020). PRKG2-PDGFRB fusion gene turned negative 7 months later from diagnosis. LESSONS: Patients with increased basophilic granulocyte and/or mast cells in peripheral blood and/or bone marrow should be screened for PDGFRB abnormality and myeloid or lymphatic tumor. Patients bearing PDGFRB abnormality have a good response to imatinib.
INTRODUCTION: Myeloid neoplasms with platelet-derived growth factor receptor β (PDGFRB) rearrangement usually present with eosinophilia in the peripheral blood and bone marrow. Here we report a case of systemic mastocytosis related myeloid neoplasms with basophilia and PRKG2-PDGFRB fusion gene. PATIENTS CONCERNS: A 53-year-old male patient felt fatigue with thrombocythemia and normal hemoglobin over 2 years. Considering the possibility of primary thrombocytosis, the patient was treated with hydroxyurea and interferon. Then the therapy was stopped due to adverse events and worsen condition. DIAGNOSIS: Acute myelogenous leukemia (AML) diagnosis was confirmed by bone marrow morphology and flow cytometry. PDGFRB rearrangement was detected by fluorescence in situ hybridization (FISH) test, with chromosome karyotype 46,XY,t(4:5)(q21:q33). PRKG2-PDGFRB fusion was observed by next generation sequencing (NGS) and verified by RT-PCR followed by Sanger sequencing. The results of bone marrow aspiration, bone marrow biopsy, and immunophenotyping showed systemic mastocytosis-related myeloid tumor with basophilia. INTERVENTIONS: Imatinib 400 mg/d was given on the day of admission. Azacitidine 75 mg/m2 was given for induction therapy for 10 days, and followed by one course of DHAG consolidating therapy. Imatinib was taken orally continuously. OUTCOMES: On the 8th day of treatment, the patient's diet and fatigue improved. The hematological and bone marrow morphological remission was achieved on the 25th day. Cytogenetic complete remission was achieved 3 months later and continued to present (December 20, 2020). PRKG2-PDGFRB fusion gene turned negative 7 months later from diagnosis. LESSONS: Patients with increased basophilic granulocyte and/or mast cells in peripheral blood and/or bone marrow should be screened for PDGFRB abnormality and myeloid or lymphatic tumor. Patients bearing PDGFRB abnormality have a good response to imatinib.
Authors: Chan Y Cheah; Kate Burbury; Jane F Apperley; Francoise Huguet; Vincenzo Pitini; Martine Gardembas; David M Ross; Donna Forrest; Philippe Genet; Philippe Rousselot; Nigel Patton; Graeme Smith; Cynthia E Dunbar; Sawa Ito; Ricardo C T Aguiar; Olatoyosi Odenike; Alla Gimelfarb; Nicholas C P Cross; John F Seymour Journal: Blood Date: 2014-03-31 Impact factor: 22.113
Authors: Animesh Pardanani; Sahrish Shah; Francesco Mannelli; Yoseph C Elala; Paola Guglielmelli; Terra L Lasho; Mrinal M Patnaik; Naseema Gangat; Rhett P Ketterling; Kaaren K Reichard; Curtis A Hanson; Alessandro M Vannucchi; Ayalew Tefferi Journal: Blood Adv Date: 2018-11-13
Authors: Christoph Walz; Georgia Metzgeroth; Claudia Haferlach; Annette Schmitt-Graeff; Alice Fabarius; Volker Hagen; Otto Prümmer; Stefan Rauh; Rüdiger Hehlmann; Andreas Hochhaus; Nicholas C P Cross; Andreas Reiter Journal: Haematologica Date: 2007-02 Impact factor: 9.941
Authors: Nitin Jain; Kathryn G Roberts; Elias Jabbour; Keyur Patel; Agda Karina Eterovic; Ken Chen; Patrick Zweidler-McKay; Xinyan Lu; Gloria Fawcett; Sa A Wang; Sergej Konoplev; Richard C Harvey; I-Ming Chen; Debbie Payne-Turner; Marcus Valentine; Deborah Thomas; Guillermo Garcia-Manero; Farhad Ravandi; Jorge Cortes; Steven Kornblau; Susan O'Brien; Sherry Pierce; Jeffrey Jorgensen; Kenna R Mills Shaw; Cheryl L Willman; Charles G Mullighan; Hagop Kantarjian; Marina Konopleva Journal: Blood Date: 2016-12-05 Impact factor: 22.113
Authors: Idoya Lahortiga; Cem Akin; Jan Cools; Todd M Wilson; Nicole Mentens; Diane C Arthur; Irina Maric; Pierre Noel; Can Kocabas; Peter Marynen; Lawrence S Lessin; Iwona Wlodarska; Jamie Robyn; Dean D Metcalfe Journal: Haematologica Date: 2008-01 Impact factor: 9.941